GILEAD FORVADE FILING HELPS STOCK FORGE 30% GAIN IN JANUARY TRADING
Executive Summary
Gilead's pursuit of expanded indications for the antiviral cidofovir is winning the company an enthusiastic following on Wall Street. Gilead closed January up 7-5/8 (30.5%) to 32-5/8